Maja Ludvigsen

Dr. Maja Ludvigsen

Aarhus University Hospital, Aarhus, Midtjylland, Denmark
+1
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Leukemia
Verified
Journal Article
Open access
PDF file
ABA Bouska
A Bouska
WZW Zhang
W Zhang
QGQ Gong
Q Gong
JIJ Iqbal
J Iqbal
ASA Scuto
A Scuto
WCWing (John) C Chan
Wing (John) C Chan
Follicular lymphoma (FL) is typically an indolent disease, but 30–40% of FL cases transform into an aggressive lymphoma (tFL) with a poor prognosis. To identify the genetic changes that drive this transformation, we sequenced the exomes of 12 cases with paired FL and tFL biopsies and identified 45 recurrently mutated genes in the FL–tFL data set and 39 in the tFL cases. We selected 496 genes of potential importance in transformation and sequenced them in 23 additional tFL cases. Integration of the mutation data with copy-number abnormality (CNA) data provided complementary information. We found recurrent mutations of miR-142, which has not been previously been reported to be mutated in FL/tFL. The genes most frequently mutated in tFL included KMT2D (MLL2), CREBBP, EZH2, BCL2 and MEF2B. Many recurrently mutated genes are involved in epigenetic regulation, the Janus-activated kinase–signal transducer and activator of transcription (STAT) or the nuclear factor-κB pathways, immune surveillance and cell cycle regulation or are TFs involved in B-cell development. Of particular interest are mutations and CNAs affecting S1P-activated pathways through S1PR1 or S1PR2, which likely regulate lymphoma cell migration and survival outside of follicles. Our custom gene enrichment panel provides high depth of coverage for the study of clonal evolution or divergence.

16 June 2011 in Blood
Verified
Journal Article
Closed access
PDF file
PKPeter M. Kamper
Peter M. Kamper
MLMaja Ludvigsen
Maja Ludvigsen
KBKnud Bendix
Knud Bendix
SHStephen Jacques Hamilton-Dutoit
Stephen Jacques Hamilton-Dutoit
GRGabriel A. Rabinovich
Gabriel A. Rabinovich
FDFrancesco D'AMore
Francesco D'AMore
Considerable effort has been spent identifying prognostic biomarkers in classic Hodgkin lymphoma (cHL). The aim of our study was to search for possible prognostic parameters in advanced-stage cHL using a proteomics-based strategy. A total of 14 cHL pretreatment tissue samples from younger, advanced-stage patients were included. Patients were grouped according to treatment response. Proteins that were differentially expressed between the groups were analyzed using 2D-PAGE and identified by liquid chromatography mass spectrometry. Selected proteins were validated using Western blot analysis. One of the differentially expressed proteins, the carbohydrate-binding protein galectin-1 (Gal-1), was further analyzed using immunohistochemistry HC and its expression was correlated with clinicopathologic and outcome parameters in 143 advanced-stage cHL cases. At the univariate level, high Gal-1 expression in the tumor microenvironment was correlated with poor event-free survival (P = .02). Among younger (≤ 61 years) patients, high Gal-1 was correlated with poorer overall and event-free survival (both P = .007). In this patient group and at the multivariate level, high Gal-1 expression retained a significant predictive impact on event-free survival. Therefore, in addition to its functional role in cHL-induced immunosuppression, Gal-1 is also associated with an adverse clinical outcome in this disease.

9 March 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
JSJohannes Frasez Soerensen
Johannes Frasez Soerensen
AAAnni Aggerholm
Anni Aggerholm
GKGitte Birk Kerndrup
Gitte Birk Kerndrup
MHMarcus Høy Hansen
Marcus Høy Hansen
IEIna Kathrine Lykke Ewald
Ina Kathrine Lykke Ewald
ARAnne Stidsholt Roug
Anne Stidsholt Roug
Therapy-related myeloid neoplasms (tMN) develop after exposure to cytotoxic and radiation therapy, and due to their adverse prognosis, it is of paramount interest to identify patients at high risk. The presence of clonal hematopoiesis has been shown to increase the risk of developing tMN. The value of analyzing hematopoietic stem cells harvested at leukapheresis before autologous stem cell transplantation (ASCT) with next-generation sequencing and immunophenotyping represents potentially informative parameters that have yet to be discovered. We performed a nested case-control study to elucidate the association between clonal hematopoiesis, mobilization potential, and aberrant immunophenotype in leukapheresis products with the development of tMN after ASCT. A total of 36 patients with nonmyeloid disease who were diagnosed with tMN after treatment with ASCT were included as case subjects. Case subjects were identified from a cohort of 1130 patients treated with ASCT and matched with 36 control subjects who did not develop tMN after ASCT. Case subjects were significantly poorer mobilizers of CD34+ cells at leukapheresis (P = .016), indicating that these patients possess inferior bone marrow function. Both clonal hematopoiesis (odds ratio, 5.9; 95% confidence interval, 1.8-19.1; P = .003) and aberrant expression of CD7 (odds ratio, 6.6; 95% confidence interval, 1.6-26.2; P = .004) at the time of ASCT were associated with an increased risk of developing tMN after ASCT. In conclusion, clonal hematopoiesis, present at low variant allele frequencies, and aberrant CD7 expression on stem cells in leukapheresis products from patients with nonmyeloid hematologic cancer hold potential for the early identification of patients at high risk of developing tMN after ASCT.

1 January 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
MSMagnus G. Snipsøyr
Magnus G. Snipsøyr
MLMaja Ludvigsen
Maja Ludvigsen
EPEskild Petersen
Eskild Petersen
HWHenrik Wiggers
Henrik Wiggers
Bent HonoréBent Honoré
Bent Honoré

8 August 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
PHPeter Hollander
Peter Hollander
PKPeter Kamper
Peter Kamper
KSKarin Ekstrom Smedby
Karin Ekstrom Smedby
GEGunilla Enblad
Gunilla Enblad
MLMaja Ludvigsen
Maja Ludvigsen
IGIngrid Glimelius
Ingrid Glimelius
Key Points: High proportions of PD-1+ and PD-L1+ leukocytes in the Hodgkin lymphoma microenvironment are associated with inferior outcome. Expression of PD-L1 and PD-L2 on Hodgkin and Reed-Sternberg cells has no impact on outcome.

13 February 2015 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
RARikke K. Andersen
Rikke K. Andersen
KHKatrine Hammer
Katrine Hammer
HHHenrik Hager
Henrik Hager
JCJulie N. Christensen
Julie N. Christensen
MLMaja Ludvigsen
Maja Ludvigsen
MMMette Madsen
Mette Madsen
Summary: We show that the multiligand receptor megalin, known to mediate uptake and trafficking of nutrients and signaling molecules, is frequently expressed in malignant melanoma samples. Expression of megalin‐encoding mRNA was investigated in 65 samples of nevi, melanomas, and melanoma metastases and was observed in more than 60% of the malignant samples, while only in 20% of the benign counterparts. Megalin expression in nevus and melanoma samples was additionally investigated by immunohistochemistry, which confirmed our mRNA‐based observations. We furthermore show that a panel of tumor‐derived melanoma cell lines express LRP2/megalin endogenously. In these cells, megalin is internalized from the cell surface and localizes extensively to intracellular vesicles, confirming receptor activity and pointing toward association with the endocytic apparatus. Groundbreaking, our results indicate that sustained megalin expression in melanoma cells is crucial for cell maintenance, as siRNA‐mediated reduction in melanoma cell expression of LRP2/megalin significantly decreases melanoma cell proliferation and survival rates.